Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04540900 · ClinicalTrials.gov registry record · Phase 1

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

A Phase 1 study of Wrinkle and Fine Lines, sponsored by Krystal Biotech.

Active
Registry status
Phase 1
Development phase
85
Enrollment target
4
Study locations

NCT04540900 is a Phase 1 study of Wrinkle and Fine Lines that is active but no longer recruiting, run by Krystal Biotech. The registered enrollment target is 85 participants, below the 117-participant average among 25 other Wrinkle trials with a reported enrollment target (27% lower). The trial reports 4 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04540900, a Phase 1 study of Wrinkle and Fine Lines, is active but no longer recruiting, sponsored by Krystal Biotech.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
85 participants
Enrollment target
4
Study locations

Study Summary

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

Interventions

  • OTHER Placebo
  • BIOLOGICAL KB301

Study Locations (4)

California

  • Aesthetx - Campbell
  • Steve Yoelin, MD Medical Associates, Inc. - Newport Beach
  • Mission Dermatology - Rancho Santa Margarita

Florida

  • Skin and Cancer Associates, LLP. D/B/A Center for Clinical and Cosmetic Research - Aventura

Trial Details

FieldValue
Enrollment Target 85 participants
Start Date 2020-10-07
Est. Completion 2029-05-31
Phase Phase 1

Sponsor

Krystal Biotech

13 total trials

What the Registry Record Tells You About NCT04540900

The ClinicalTrials.gov registry entry for NCT04540900 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 117-participant average among 25 other Wrinkle trials with a reported enrollment target (27% lower). The listed sponsor is Krystal Biotech, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Wrinkle appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04540900 reports 4 study locations spanning 2 distinct geographic areas - top geographies include California, Florida.

Frequently Asked Questions

What is clinical trial NCT04540900 about?

NCT04540900 is a clinical study titled "A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions". A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

What is the current status of trial NCT04540900?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2020-10-07. Estimated completion is 2029-05-31.

What conditions does trial NCT04540900 study?

This clinical trial studies the following conditions: Wrinkle, Fine Lines, Skin Roughness, Skin Thickness.

What interventions are being tested in trial NCT04540900?

The interventions under investigation include: Placebo (OTHER), KB301 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04540900?

This trial is sponsored by Krystal Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04540900 being conducted?

This trial has 4 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Wrinkle

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.